Enovis (NYSE:ENOV) Shares Up 14.1% – Should You Buy?

Enovis Corporation (NYSE:ENOV) shares were up 14.1% during mid-day trading on Wednesday. The company traded as high as $24.01 and last traded at $23.8440. 205,270 shares were traded during trading, a decline of 83% from the average daily volume of 1,233,179 shares. The stock had previously closed at $20.89.

Key Headlines Impacting Enovis

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Q3 earnings beat estimates: Enovis reported adjusted earnings of $0.88 per share, above the $0.77 consensus and up from $0.75 a year earlier. Revenue of $558.7 million edged past expectations and rose 1.8% year over year. Enovis Q3 2026 results
• Positive Sentiment: Higher outlook and buyback: The company raised its 2026 EPS guidance to $3.58–$3.79 and authorized a $200 million share repurchase program. The higher forecast signals improved earnings expectations; repurchases may also support per-share results. Guidance and buyback announcement
• Positive Sentiment: Analysts lifted price targets: Wells Fargo raised its target to $37 and kept an Overweight rating; Needham raised its target to $38 with a Buy rating, and BTIG raised its target to $42 with a Buy rating. These revisions reflect more optimistic analyst views following the results. Wells Fargo ratings
• Neutral Sentiment: Despite these positive updates, ENOV was lower in the supplied trading snapshot. The available reports do not cite a specific negative development explaining the weakness.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ENOV. BMO Capital Markets set a $27.00 price objective on shares of Enovis in a research report on Tuesday, September 1st. Zacks Research raised shares of Enovis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. UBS Group restated a “buy” rating and set a $44.00 price target on shares of Enovis in a research note on Monday, October 5th. Wells Fargo & Company raised their price target on shares of Enovis from $33.00 to $37.00 and gave the company an “overweight” rating in a report on Friday. Finally, Citigroup restated a “market outperform” rating on shares of Enovis in a report on Wednesday, September 2nd. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $39.00.

Enovis Stock Down 4.5%

The company has a debt-to-equity ratio of 0.84, a current ratio of 1.98 and a quick ratio of 1.00. The stock has a market capitalization of $1.58 billion, a P/E ratio of -1.41 and a beta of 1.31. The firm has a 50 day moving average of $19.86 and a 200-day moving average of $23.07.

Enovis (NYSE:ENOV) last posted its earnings results on Thursday, November 5th. The company reported $0.88 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.11. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The business had revenue of $558.73 million for the quarter, compared to analysts’ expectations of $557.12 million. During the same quarter in the previous year, the firm posted $0.75 earnings per share. The firm’s revenue for the quarter was up 1.8% on a year-over-year basis. On average, equities research analysts expect that Enovis Corporation will post 3.15 earnings per share for the current fiscal year.

Insider Buying and Selling at Enovis

In other Enovis news, CEO Damien Mcdonald bought 13,035 shares of Enovis stock in a transaction dated Friday, September 4th. The shares were bought at an average price of $19.15 per share, with a total value of $249,620.25. Following the purchase, the chief executive officer owned 247,077 shares of the company’s stock, valued at $4,731,524.55. This trade represents a 5.57% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Oliver Engert acquired 5,140 shares of Enovis stock in a transaction on Thursday, September 3rd. The stock was acquired at an average cost of $19.46 per share, for a total transaction of $100,024.40. Following the completion of the purchase, the insider owned 61,238 shares of the company’s stock, valued at approximately $1,191,691.48. The trade was a 9.16% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have acquired 23,293 shares of company stock worth $449,599. Company insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Enovis

Large investors have recently made changes to their positions in the stock. Maryland State Retirement & Pension System bought a new position in shares of Enovis in the third quarter valued at approximately $238,000. Illinois Municipal Retirement Fund increased its position in shares of Enovis by 22.4% during the third quarter. Illinois Municipal Retirement Fund now owns 38,366 shares of the company’s stock valued at $701,000 after acquiring an additional 7,028 shares during the last quarter. Private Management Group Inc. increased its position in shares of Enovis by 31.3% during the third quarter. Private Management Group Inc. now owns 1,792,429 shares of the company’s stock valued at $32,748,000 after acquiring an additional 427,347 shares during the last quarter. Fulcrum Asset Management LLP lifted its holdings in Enovis by 2,739.4% during the third quarter. Fulcrum Asset Management LLP now owns 20,330 shares of the company’s stock worth $375,000 after acquiring an additional 19,614 shares during the period. Finally, Villanova Investment Management Co lifted its holdings in Enovis by 10.2% during the third quarter. Villanova Investment Management Co now owns 148,424 shares of the company’s stock worth $2,712,000 after acquiring an additional 13,740 shares during the period. Institutional investors own 98.45% of the company’s stock.

Enovis Company Profile

Enovis Corporation (NYSE: ENOV) is a medical technology company that develops, manufactures and distributes products designed to improve patient recovery, mobility and quality of life. Its portfolio serves orthopedic, sports medicine, physical therapy and rehabilitation markets, as well as other areas of musculoskeletal care.

The company’s products include orthopedic implants and surgical technologies, braces and supports, cold and compression therapy systems, electrotherapy and rehabilitation equipment, and other solutions used by hospitals, surgeons, physical therapists, athletic trainers and patients.